PriceTargets.com logo

Sensei Biotherapeutics - FTH Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $56.25
  • Forecasted Upside: 200.96%
  • Number of Analysts: 17
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 12 Buy Ratings
  • 3 Strong Buy Ratings
$18.69 As of 10/30/2026 05:00 PM ET
▼ -0.06 (-0.32%)

This chart shows the closing price for FTH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sensei Biotherapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FTH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FTH

Analyst Price Target is $56.25
▲ +200.96% Upside Potential
This price target is based on 17 analysts offering 12 month price targets for Sensei Biotherapeutics in the last 3 months. The average price target is $56.25, with a high forecast of $70.00 and a low forecast of $50.00. The average price target represents a 200.96% upside from the last price of $18.69.

This chart shows the closing price for FTH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 17 investment analysts is to buy stock in Sensei Biotherapeutics. This rating changed within the last month from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 1 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/8/2025
  • 1 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/6/2025
  • 1 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 1 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
2/2/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
5/3/2026
  • 1 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
8/1/2026
  • 2 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
9/30/2026
  • 3 strong buy ratings
  • 12 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
10/30/2026

Latest Recommendations

  • 3 strong buy ratings
  • 12 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/27/2026BTIG ResearchReiterated RatingBuy ➝ Buy$55.00
10/16/2026William BlairInitiated CoverageOutperform
10/15/2026Lifesci CapitalUpgradeStrong-Buy
9/16/2026GuggenheimInitiated CoverageBuy$70.00
9/15/2026GuggenheimUpgradeStrong-Buy
9/14/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/9/2026TD CowenInitiated CoverageBuy
8/21/2026Needham & Company LLCInitiated CoverageBuy$56.00
8/11/2026HC WainwrightReiterated RatingBuy ➝ Buy$60.00
8/4/2026JonesTradingInitiated CoverageBuy$55.00
7/31/2026Raymond James FinancialInitiated CoverageOutperform$56.00
7/28/2026OppenheimerInitiated CoverageOutperform$60.00
7/20/2026Citizens JmpInitiated CoverageOutperform$51.00
7/16/2026BTIG ResearchReiterated RatingBuy ➝ Buy$55.00
6/26/2026Robert W. BairdInitiated CoverageOutperform$57.00
6/25/2026Robert W. BairdUpgradeStrong-Buy
6/22/2026HC WainwrightInitiated CoverageHold ➝ Buy$60.00
6/17/2026Weiss RatingsInitiated CoverageSell (D-)
6/11/2026BTIG ResearchUpgradeStrong-Buy
6/11/2026BTIG ResearchInitiated CoverageBuy ➝ Buy$55.00
6/4/2026Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight
5/29/2026Cantor FitzgeraldInitiated CoverageOverweight
5/28/2026Loop CapitalSet Target$50.00
5/22/2026CitigroupInitiated CoverageBuy ➝ Buy$55.00
4/24/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
4/21/2026Zacks ResearchUpgradeHold
4/20/2026Leerink PartnersInitiated CoverageOutperform$50.00
12/29/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/22/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
12/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/19/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/13/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/30/2025HC WainwrightDowngradeBuy ➝ Neutral
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
8/5/2025HC WainwrightReiterated RatingBuy ➝ Buy$30.00
6/2/2025HC WainwrightUpgradeBuy$100.00
5/1/2025StephensUpgradeStrong-Buy
3/28/2025OppenheimerBoost TargetOutperform ➝ Outperform$70.00 ➝ $80.00
3/28/2025HC WainwrightReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
1/8/2025HC WainwrightReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
8/7/2024HC WainwrightReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
6/3/2024CitigroupReiterated RatingBuy ➝ Buy$80.00
5/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
5/24/2024StephensReiterated RatingOverweight ➝ Overweight$100.00 ➝ $100.00
5/14/2024StephensInitiated CoverageOverweight$100.00
12/4/2023HC WainwrightReiterated RatingBuy$80.00
12/13/2022CitigroupInitiated CoverageBuy
10/3/2022OppenheimerUpgradeMarket Perform ➝ Outperform
3/10/2022Piper SandlerLower TargetOverweight$240.00 ➝ $200.00
(Data available from 10/31/2021 forward)

News Sentiment Rating

0.38 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2026
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2026
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
6/2/2026
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2026
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/1/2026
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/31/2026
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/30/2026
  • 6 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
10/30/2026

Current Sentiment

  • 6 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Sensei Biotherapeutics logo
Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
Read More

Today's Range

Now: $18.69
Low: $17.88
High: $19.04

50 Day Range

MA: $28.80
Low: $16.83
High: $40.05

52 Week Range

Now: $18.69
Low: $7.45
High: $42.14

Volume

510,969 shs

Average Volume

370,423 shs

Market Capitalization

$482.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Sensei Biotherapeutics?

The following sell-side analysts have issued reports on Sensei Biotherapeutics in the last twelve months: BTIG Research, Cantor Fitzgerald, Citigroup Inc., Citizens Jmp, Guggenheim, HC Wainwright, JonesTrading, Leerink Partners, Lifesci Capital, Loop Capital, Needham & Company LLC, Oppenheimer Holdings, Inc., Raymond James Financial, Inc., Robert W. Baird, TD Cowen, Wall Street Zen, Weiss Ratings, William Blair, and Zacks Research.
View the latest analyst ratings for FTH.

What is the current price target for Sensei Biotherapeutics?

0 Wall Street analysts have set twelve-month price targets for Sensei Biotherapeutics in the last year. Their average twelve-month price target is $56.25, suggesting a possible upside of 201.0%. Guggenheim has the highest price target set, predicting FTH will reach $70.00 in the next twelve months. Leerink Partners has the lowest price target set, forecasting a price of $50.00 for Sensei Biotherapeutics in the next year.
View the latest price targets for FTH.

What is the current consensus analyst rating for Sensei Biotherapeutics?

Sensei Biotherapeutics currently has 1 sell rating, 1 hold rating, 12 buy ratings and 3 strong buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe FTH will outperform the market and that investors should add to their positions of Sensei Biotherapeutics.
View the latest ratings for FTH.

What other companies compete with Sensei Biotherapeutics?

Other companies that are similar to Sensei Biotherapeutics include AbbVie, AbCellera Biologics, Abeona Therapeutics, Absci and AC Immune. Learn More about companies similar to Sensei Biotherapeutics.

How do I contact Sensei Biotherapeutics' investor relations team?

Sensei Biotherapeutics' physical mailing address is 701 Tillery Street #12 #1010, Austin, TX, 78702. The company's listed phone number is (512) 200-2982 and its investor relations email address is [email protected]. The official website for Sensei Biotherapeutics is www.faeththerapeutics.com. Learn More about contacing Sensei Biotherapeutics investor relations.